{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000728","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.155803+00:00","generated_at":"2026-06-15T20:40:12.186578+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Alnylam Q1 product rev $276M (+48% YoY); ALN-APP CNS data positive; FY guidance reaffirmed","bullets":["Q1 net product revenue $276M (+48% YoY); AMVUTTRA $102M and ONPATTRO $102M drove TTR growth of 49%.","GAAP net loss $174M ($1.40/share); non-GAAP net loss $132M ($1.06/share). FY23 revenue guidance $1.2B-$1.285B reaffirmed.","Positive interim Phase 1 data for ALN-APP in early-onset Alzheimer's: first human RNAi CNS gene silencing demonstrated.","18-month APOLLO-B data submitted to FDA for ONPATTRO in cardiomyopathy; KARDIA-1 (zilebesiran) topline expected mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000728","json":"https://secwatch.observer/filing/0001157523-23-000728.json","markdown":"https://secwatch.observer/filing/0001157523-23-000728.md","text":"https://secwatch.observer/filing/0001157523-23-000728.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000115752323000728/0001157523-23-000728-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000115752323000728/a53393280.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:40:12.186578+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2bf7735c3b4bb12583d9e0b35366f162dd3ebbc5","claim":"ALNYLAM PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2023 results: revenue $276 Million. Guidance reaffirmed.","evidence_excerpt":"− Achieved First Quarter 2023 Global Net Product Revenues of $276 Million, Representing 48% Year-Over-Year Growth Compared to Q1 2022 –","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000115752323000728/0001157523-23-000728-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$276 Million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}